2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Conditions
Polycystic Ovary Syndrome
6
Obesity
5
Sexual Infantilism
4
Craniopharyngioma
3
Pancreatic Neoplasms
2
Overweight
2
Weight Loss
1
Insulin Resistance
1
Fatty Liver
1
Diabetes Mellitus, Type 2
1
Diabetes Mellitus, Type 1
1
Interventions
Exercise
10
Diet
6
Caloric Restriction
5
Nutrition Assessment
4
Metformin
4
Octreotide
3
Megestrol Acetate
3
Cognitive Behavioral Therapy
3
anamorelin
2
Standard of Care
2
Olanzapine
2
Mirtazapine
2
Melatonin
2
Liraglutide
2
Eicosapentaenoic Acid
2
Diet, Carbohydrate-Restricted
2
Diet Therapy
2
sibutramine
1
remune
1
olanzapine-fluoxetine combination
1
lime
1
irinotecan sucrosofate
1
bermekimab
1
Weight Reduction Programs
1
Urine Specimen Collection
1
Tirzepatide
1
TOPS
1
Surveys and Questionnaires
1
Sugars
1
Sampling Studies
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Weight Loss
×
Exenatide
×
Clear all
NCT02664441
2022-05-05
ECHO
Seattle Children's Hospital
Phase 3
Completed
42 enrolled
26 charts